The Metabolic Roots of High Blood Pressure: Why Cutting Salt Is Rarely the Whole Story
Executive summary
Reducing dietary salt does lower blood pressure on average, but the effect is modest and varies widely between individuals. It is larger in people who are older, salt-sensitive, or already hypertensive, and smaller in everyone else (Ref 1, Ref 2, Ref 3).
Insulin is a sodium-retaining hormone. In a classic human study, an insulin infusion given while blood glucose was held steady reduced the kidney's sodium excretion by about half, which can expand blood volume (Ref 12).
Chronically raised insulin, or hyperinsulinaemia, travels closely with hypertension. Whether it causes sustained high blood pressure on its own is genuinely debated, and it is probably one contributing mechanism among several rather than a single cause (Ref 14, Ref 15).
Because dietary carbohydrate is the main stimulus for insulin, lower-carbohydrate diets tend to prompt early sodium and water loss and small reductions in blood pressure, alongside weight loss and lower triglycerides. The average blood-pressure effect is modest, and the cholesterol carried on LDL particles can rise (Ref 16).
Magnesium supplementation lowers blood pressure by a small amount on average, roughly 2 mmHg systolic, possibly more in people who are insulin-resistant or genuinely deficient. The trials are heterogeneous and often of modest quality (Ref 4, Ref 5, Ref 6, Ref 7).
Mineral intake is not the same as mineral status. Plant compounds such as phytate reduce absorption of some minerals, strongly for iron and zinc and more modestly for magnesium (Ref 9, Ref 10).
Uric acid, which fructose raises, may impair nitric-oxide-dependent relaxation of blood vessels. This is mechanistically plausible but rests largely on animal and cell studies, so human causal evidence is still limited (Ref 18, Ref 19, Ref 20, Ref 26).
Potassium relative to sodium matters more than sodium alone. Potassium lowers blood pressure most when sodium intake is high, and partially replacing sodium with potassium reduced strokes and deaths in a large trial, with an important caution in kidney disease (Ref 21, Ref 22, Ref 23).
High blood pressure, technically hypertension, is usually explained to patients in a single line: eat less salt. For some people that helps. For many it does little, and the reason, I will argue, is that salt is often a symptom rather than the root cause.
I should declare my starting point before making that case. I run a private clinic and offer paid consultations, so I have a commercial interest in people valuing this kind of analysis. I also work through a metabolic, lower-carbohydrate lens, which shapes how I read the literature. I have tried to counter that below by citing the mainstream salt evidence at its strongest and by flagging where my interpretation runs ahead of what the data can carry. Every study I mention is referenced, and I have noted the limitations of each rather than only its headline.
The salt story: real, but modest and incomplete
Two large, careful reviews anchor the conventional view. A Cochrane analysis of 34 trials found that cutting salt by roughly 4.4 g per day lowered systolic blood pressure by about 4 mmHg overall, and by around 5.4 mmHg in people with hypertension (Ref 1). A 2020 analysis of 133 trials and more than 12,000 people found a dose-response relationship, with each 50 mmol reduction in daily sodium associated with roughly a 1 mmHg fall in systolic pressure, and larger effects in older and hypertensive people (Ref 2). So salt reduction genuinely lowers blood pressure. That is not in serious dispute, and I will not pretend otherwise.
The honest caveats are that the average effect is small, the trials are statistically heterogeneous, and the response is very uneven between individuals. That unevenness has a name: salt sensitivity. Only a subset of people show a large pressure rise with sodium, and the mechanisms behind it, genetic, hormonal, renal, and immune, are still only partly understood (Ref 3). The practical problem with "everyone eat less salt" is that it treats a population average as if it were an individual prescription, and it leaves the upstream question unasked: why is this person's system handling sodium poorly in the first place? For many, the answer runs through insulin.
Insulin, the kidney, and sodium retention
Insulin does far more than move glucose. One of its jobs is to tell the kidney to hold on to sodium. The cleanest demonstration is nearly fifty years old. When researchers infused insulin into healthy volunteers while clamping blood glucose at its normal level, urinary sodium excretion fell by about half, with no change in filtration rate or in aldosterone (Ref 12). The kidney simply reabsorbed more sodium. Where sodium goes, water follows, and a larger blood volume raises pressure in the circulation, much as adding water to a closed network of pipes raises the pressure inside it. The same direction of effect appears in animal work, where insulin treatment reliably causes sodium retention in rodents (Ref 13, an animal study, so its human relevance is indirect).
Here I have to be careful, because this point is often overstated. Showing that insulin acutely retains sodium is not the same as proving that chronically high insulin causes lasting hypertension. When researchers infused insulin into dogs for weeks, blood pressure did not rise, whereas in rats it did (Ref 15). Reviews of the human data conclude that insulin resistance and hyperinsulinaemia are consistently associated with high blood pressure and plausibly act as a slow, amplifying pressure mechanism, but that obesity-related hypertension is too complex to pin on insulin alone (Ref 14, Ref 15). My reading is that hyperinsulinaemia is one important lever, particularly in people who are also salt-sensitive, rather than the only one.
Carbohydrate load and hyperinsulinaemia
If insulin is a lever on blood pressure, the main dietary control on insulin is carbohydrate. Eating carbohydrate raises blood glucose, and insulin rises to return it to its set point. Do this repeatedly against a background of excess body fat and inactivity, and cells respond less to insulin's signal, so the body secretes still more insulin to achieve the same result. That is pathological insulin resistance, and it keeps circulating insulin chronically high.
It is worth separating this from a different, benign state. A person adapted to a very-low-carbohydrate diet can also show reduced glucose tolerance, but this is an adaptive, physiological form of insulin resistance that spares glucose for tissues such as the brain. It is not the same process as the hyperinsulinaemia of metabolic disease. The distinction matters when someone worries that their fasting glucose drifted upward on a low-carbohydrate diet.
What happens to blood pressure when carbohydrate is reduced? A meta-analysis of 13 randomised trials found that very-low-carbohydrate diets produced modestly greater weight loss and a small fall in diastolic blood pressure compared with low-fat diets, along with lower triglycerides and higher HDL, although the cholesterol carried on LDL particles rose modestly (Ref 16). The blood-pressure effect was real but small on average. Part of it is likely the early natriuresis described above: as insulin falls, the kidney stops over-retaining sodium and water, and losing that extra fluid is why people often shed several pounds of water in the first week. That is a plausible mechanism rather than a proven chain in every individual. There is also a mechanistic thread linking sugar specifically to salt handling. In mice, a fructose-rich diet sensitised blood pressure to salt through an insulin-activated sodium channel in the kidney, and removing that pathway blunted the effect (Ref 17, animal work). It is a clue, not human proof, but it fits the pattern.
Magnesium: a small but plausible contribution
Magnesium relaxes blood vessels, at least in principle. It behaves as a natural calcium antagonist and supports the production of nitric oxide (NO) and prostacyclin, the local signals that tell arteries to widen (Ref 7). It helps to picture nitric oxide as the brake-release on vascular tone, and magnesium as one of the things that keeps that release working.
The trial evidence is real but modest. The best pooled analysis, 34 randomised double-blind trials in more than 2,000 people, found magnesium supplementation lowered systolic pressure by about 2 mmHg and diastolic by about 1.8 mmHg (Ref 4). A Cochrane review was more sceptical still, concluding that the apparent benefit was small and probably inflated by lower-quality studies (Ref 5). Some popular summaries quote considerably larger reductions, but the higher-quality pooled estimates are smaller, and it is those I would trust. Where magnesium may do more is in metabolically impaired people: in trials restricted to those with insulin resistance, prediabetes, or chronic disease, the reductions were larger, around 4 mmHg systolic (Ref 6).
Is deficiency common enough to matter? Population magnesium status is genuinely hard to measure, because blood levels are held stable at the expense of tissue stores, so a normal serum value can mask depletion. Some surveys of apparently healthy adults find a substantial fraction below reference thresholds (Ref 8, a small single study, so treat it as suggestive rather than settled). My own clinical use of magnesium is as time-limited support while the diet is corrected, not as a treatment in its own right.
Antinutrients, bioavailability, and the soil question
This undermines the simple instruction to "just eat more vegetables for your minerals": how much of a mineral you swallow is not how much you absorb. Plant foods contain compounds that bind minerals in the gut, and phytate, or phytic acid, is the best studied. In a controlled human experiment, adding phytate to bread at amounts found naturally in wholemeal cut magnesium absorption from about 33% to 13% (Ref 9).
The fair counterpoint is that phytate's grip is not equal across minerals. Reviews conclude that it strongly inhibits iron and zinc absorption, while its effect on magnesium and calcium is more modest (Ref 10). So the antinutrient argument is genuine but should not be inflated. It is a reason to value animal foods, which are largely free of these binders and deliver minerals in more absorbable forms, and a reason not to assume a leafy salad equals its label.
A related claim is that produce is simply less nutritious than it used to be. The most cited analysis compared 43 garden crops between 1950 and 1999 and found median declines of 6% to 38% for six nutrients (Ref 11). The same authors were candid about the limits, though: many individual changes were not statistically reliable, some nutrients actually rose, and the likeliest explanation is not exhausted soil but the shift to higher-yielding varieties that trade nutrient density for size. It is a modest, real signal that supports choosing nutrient-dense foods, not a dramatic story of empty vegetables.
Uric acid and fructose
Uric acid is usually discussed only in the context of gout, but it may also affect blood-vessel function. Fructose, from added sugar and from large quantities of fruit, is a notable driver of uric acid production. In cell and animal studies, raised uric acid reduces nitric oxide availability and impairs the ability of arteries to relax, and it appears to interfere specifically with insulin's own vessel-widening action (Ref 20, Ref 26, both largely animal and cell work, so human relevance is inferred). Reviews of the human epidemiology find that elevated uric acid predicts the later onset of hypertension, especially in the young, and set out a plausible mechanism through nitric oxide and the renin-angiotensin system (Ref 18, Ref 19).
I want to stay measured. Most of the direct mechanistic evidence is not from humans, and trials of uric-acid-lowering drugs to treat blood pressure have given mixed results. So the honest statement is that it is plausible that high uric acid, driven by fructose against a high-carbohydrate background, contributes to blood-pressure problems in some people, and that it can be worth measuring in the right context. It is not that lowering uric acid is a proven blood-pressure treatment.
Potassium and the sodium-potassium balance
Sodium does not act alone. It works against potassium, and the balance between the two is more informative than either in isolation. Potassium supplementation lowers blood pressure by around 3 mmHg systolic on average, and, tellingly, the effect is largest when sodium intake is high (Ref 21). A dose-response analysis confirmed the relationship but also showed it is not linear: the benefit plateaus, and very high potassium intakes are not clearly better and may carry risk in some groups (Ref 22).
The strongest evidence comes from hard outcomes rather than pressure readings alone. In a trial of nearly 21,000 people at high cardiovascular risk, replacing a quarter of ordinary salt with potassium chloride reduced strokes, major cardiovascular events, and deaths (Ref 23). The essential safety caveat is that potassium is dangerous in people with impaired kidney function or on certain blood-pressure medications, in whom the same substitution can cause harmful potassium retention. This is precisely why a blanket rule is a poor substitute for individual assessment. And, again, potassium-rich plants carry the antinutrients discussed above, so the gap between intake and absorption applies here too.
When the problem is structural, not metabolic
Everything so far concerns what I would call metabolic hypertension: pressure driven by volume, hormones, and vascular signalling, which can shift relatively quickly. There is a second category. With age and prolonged metabolic stress, arteries stiffen and lose elasticity, and stiff pipes carry higher pressure regardless of volume. Magnesium deficiency itself has been proposed as one contributor to that stiffening (Ref 7).
Structural change is slower to move, and I would not promise anyone that it fully reverses. The reasonable goal is to stop it worsening and to give the vessel wall the conditions to remodel over months: a sustained low insulin load, adequate minerals, movement, sleep, and sunlight. One popular mechanistic idea is that vitamins D3 and K2 help keep calcium in bone and out of arterial walls. It is biologically plausible, but the human evidence is thin. A vitamin K2 (menaquinone) study reporting effects on arterial stiffness, for example, was a small, uncontrolled, single-arm trial of 26 people, which cannot establish benefit (Ref 24). I mention it as a hypothesis to watch, not a recommendation.
What this means in practice
The single question I keep returning to for any test or intervention is whether it changes what I would actually do. For blood pressure, the answer reorders the usual advice.
First, look upstream. If someone has hypertension alongside excess weight, a high-carbohydrate diet, or markers of insulin resistance, the highest-leverage change is usually reducing the insulin load through diet, not shaving grams off salt. The blood-pressure fall on lower-carbohydrate eating is modest on average (Ref 16), but it arrives bundled with weight, triglyceride, and glucose improvements, and it addresses a plausible root rather than a symptom.
Second, transition at a pace that suits the person. Someone eating carbohydrate throughout the day may need months, whereas someone already eating mostly protein and fat may need only weeks.
Third, treat supplements as temporary scaffolding, not the building. Magnesium and potassium can help while the diet is corrected, within the safety limits above, but the aim is to restore the body's own ability to handle minerals from food.
Fourth, move. A meta-analysis of 93 trials and more than 5,000 people found that regular endurance and resistance training lower resting blood pressure, with the largest reductions in people who are already hypertensive (Ref 25).
Finally, a caution that matters more than any of the above. None of this is a reason to stop prescribed blood-pressure medication. If you want to change your treatment, do it with the clinician who prescribed it, using these ideas to inform that conversation rather than to replace it. Salt is not the enemy for most people. A system that cannot handle salt is the problem worth fixing.
Disclosures
I run a private clinic and offer paid consultations, so I benefit commercially when readers find this kind of analysis useful. I work primarily through a metabolic and lower-carbohydrate lens, and my interests in nutrition and metabolic medicine predispose me to emphasise insulin over sodium. I have tried to counter that bias by citing the mainstream salt-reduction evidence at its strongest and by noting the limitations of every study, including those that support my view. Nothing here is individual medical advice. If you would like help applying this to your own circumstances I offer consultations, though there are many excellent clinicians who work this way and you do not have to see me.
References
He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ, 2013. https://doi.org/10.1136/bmj.f1325
Huang L, Trieu K, Yoshimura S, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ, 2020. https://doi.org/10.1136/bmj.m315
Luzardo L, Noboa O, Boggia J. Mechanisms of Salt-Sensitive Hypertension. Current Hypertension Reviews, 2015. https://doi.org/10.2174/1573402111666150530204136
Zhang X, Li Y, Del Gobbo LC, et al. Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials. Hypertension, 2016. https://doi.org/10.1161/HYPERTENSIONAHA.116.07664
Dickinson HO, Nicolson DJ, Campbell F, et al. Magnesium supplementation for the management of essential hypertension in adults. Cochrane Database of Systematic Reviews, 2006. https://doi.org/10.1002/14651858.CD004640.pub2
Dibaba DT, Xun P, Song Y, et al. The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, 2017. https://doi.org/10.3945/ajcn.117.155291
Kostov K, Halacheva L. Role of Magnesium Deficiency in Promoting Atherosclerosis, Endothelial Dysfunction, and Arterial Stiffening as Risk Factors for Hypertension. International Journal of Molecular Sciences, 2018. https://doi.org/10.3390/ijms19061724
Sales CH, Nascimento DA, Medeiros ACQ, et al. There is chronic latent magnesium deficiency in apparently healthy university students. Nutricion Hospitalaria, 2014. https://doi.org/10.3305/nh.2014.30.1.7510
Bohn T, Davidsson L, Walczyk T, Hurrell RF. Phytic acid added to white-wheat bread inhibits fractional apparent magnesium absorption in humans. American Journal of Clinical Nutrition, 2004. https://doi.org/10.1093/ajcn/79.3.418
Hurrell RF. Influence of vegetable protein sources on trace element and mineral bioavailability. Journal of Nutrition, 2003. https://doi.org/10.1093/jn/133.9.2973S
Davis DR, Epp MD, Riordan HD. Changes in USDA food composition data for 43 garden crops, 1950 to 1999. Journal of the American College of Nutrition, 2004. https://doi.org/10.1080/07315724.2004.10719409
DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. Journal of Clinical Investigation, 1975. https://doi.org/10.1172/JCI107996
Blumenthal SA. Observations on sodium retention related to insulin treatment of experimental diabetes. Diabetes, 1975. https://doi.org/10.2337/diab.24.7.645
Weidmann P, Bohlen L, de Courten M. Insulin resistance and hyperinsulinemia in hypertension. Journal of Hypertension (Supplement), 1995. https://doi.org/10.1097/00004872-199508001-00010
Brands MW, Hall JE. Insulin resistance, hyperinsulinemia, and obesity-associated hypertension. Journal of the American Society of Nephrology, 1992. https://doi.org/10.1681/ASN.V351064
Bueno NB, de Melo IS, de Oliveira SL, da Rocha Ataide T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. British Journal of Nutrition, 2013. https://doi.org/10.1017/S0007114513000548
Huang DY, Boini KM, Friedrich B, et al. Blunted hypertensive effect of combined fructose and high-salt diet in gene-targeted mice lacking functional serum- and glucocorticoid-inducible kinase SGK1. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, 2005. https://doi.org/10.1152/ajpregu.00382.2005
Mene P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? Journal of Hypertension, 2008. https://doi.org/10.1097/HJH.0b013e32830e4945
Feig DI, Kang DH, Nakagawa T, Mazzali M, Johnson RJ. Uric acid and hypertension. Current Hypertension Reports, 2006. https://doi.org/10.1007/s11906-006-0005-z
Choi YJ, Yoon Y, Lee KY, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB Journal, 2014. https://doi.org/10.1096/fj.13-247148
Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. JAMA, 1997. https://doi.org/10.1001/jama.1997.03540440058033
Filippini T, Naska A, Kasdagli MI, et al. Potassium Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2020. https://doi.org/10.1161/JAHA.119.015719
Neal B, Wu Y, Feng X, et al. Effect of Salt Substitution on Cardiovascular Events and Death. New England Journal of Medicine, 2021. https://doi.org/10.1056/NEJMoa2105675
Ikari Y, Torii S, Shioi A, Okano T. Impact of menaquinone-4 supplementation on coronary artery calcification and arterial stiffness: an open label single arm study. Nutrition Journal, 2016. https://doi.org/10.1186/s12937-016-0175-8
Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. Journal of the American Heart Association, 2013. https://doi.org/10.1161/JAHA.112.004473
Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney International, 2005. https://doi.org/10.1111/j.1523-1755.2005.00273.x
